PATENT CLAIM ANALYSIS

Application Number: 15944894
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["424", "400000"]

Abstract:
The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.

Claim (Index 1):
A method of treating a disease, disorder or condition that is therapeutically responsive to a risperidone, the method comprising administering to a subject in need thereof an amount of injectable depot composition to form an implant in the subject, wherein the amount is sufficient provide a therapeutic dose of risperidone, whereby the implant provides therapeutic plasma levels of the risperidone from within 1 day after administration throughout a dosing period of at least two weeks following administration thereof, wherein the injectable depot composition consists of:\n risperidone present as particles having a particle size distribution as follows: not more than 10% of the total volume of risperidone particles is less than 10 microns in size, not more than 10% of the total volume of risperidone particles is greater than 225 microns in size, and the d0.5 of the size distribution is in the range of about 60-130 microns; and polymeric solution consisting of:\n DMSO; and \n biocompatible poly(lactide-co-glycolide) (PLGA) copolymer comprising lactic acid and glycolic acid monomers, wherein the monomers are present at a monomer ratio of lactic to glycolic acid of 48:52 to 52:48, the copolymer has an inherent viscosity in the range of 0.25-0.48 dl/g as measured in chloroform at 25\u00b0 C. and at a concentration of 0.1% wt/v with an Ubbelohde size 0c glass capillary viscometer; wherein \n the polymeric solution has a viscosity in the range of about 0.7 Pa\u00b7s to about 3.0 Pa\u00b7s; and wherein the risperidone content is about 13% wt with respect to the total composition weight; the DMSO to risperidone mass ratio is about 4:1 to 5:1; and the polymeric solution to risperidone mass ratio is about 6.5:1 to 7:1.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 91.0
- Lexical Diversity: 1.62025
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13690647', '13690707', '14555287', '14555273', '14610362']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7571681901437158
- 35 USC 102 Novelty (BERT): 0.6382964385963574
- Combined Prediction Score: 0.74528101498898
- Mean Citation Score: 487.32386800000006
- Max Citation Score: 725.46405
- Similarity Product: 528.4201383414925

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test